Application No.: 10/552,194 Restriction Requirement mailed October 25, 2007 Amendment filed February 21, 2008

Page 2 of 5

Listing of the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- (ORIGINAL) A device comprising an extracellular matrix having an internal pH between 4.0 and 6.0, wherein the extracellular matrix contains heparin or a heparinrelated compound bound to a protein, wherein the protein has a pH dependent binding to the heparin or the heparin-related compound.
- (ORIGINAL) The device of claim 1, wherein the internal pH is between 5 and 6.
- (ORIGINAL) The device of claim 1, wherein the internal pH is about 5.5.
- (ORIGINAL) The device of claim 1, wherein the bound protein is VEGF.
- (PREVIOUSLY PRESENTED) The device of claim 1, wherein the extracellular matrix further comprises fibronectin or a fibronectin fragment that binds to the bound protein.
- (CANCELED)
- (ORIGINAL) The device of claim 1, wherein the heparin-related compound is heparan sulfate or heparan sulfate proteoglycan.
- (PREVIOUSLY PRESENTED) The device of claim 1, wherein the bound protein contains a heparin-binding consensus sequence.
- (ORIGINAL) The device of claim 8, wherein the heparin-binding consensus sequence is XBBBXXBX or XBBXBX, where B is a basic amino acid residue or His and X is any amino acid residue.
- 10. (PREVIOUSLY PRESENTED) The device of claim 1, wherein the bound protein contains a glycine-like box, wherein said glycine-like box is from about seven to twelve amino acids and contains at least two Gly residues and two-five basic amino acid residues.

Application No.: 10/552,194 Restriction Requirement mailed October 25, 2007 Amendment filed February 21, 2008

Page 3 of 5

- 11. (ORIGINAL) The device of claim 1, wherein the glycine-like box is SEQ ID NO:1.
- (ORIGINAL) The device of claim 11, wherein the bound protein is VEGF121 or VEGF165.
- (PREVIOUSLY PRESENTED) The device of claim 1, wherein the device is formed in situ in a subject.
- 14. (PREVIOUSLY PRESENTED) A kit for making the device of claim 1, wherein the kit contains a vial containing heparin or a heparin-related compound and a second vial containing fibronectin or a protein containing a heparin-bind domain.
- 15. (PREVIOUSLY PRESENTED) The device of claim 1, wherein the extracellular matrix is attached to or encased within a compound selected from the group consisting of a film, a hydrocolloid, a hydrogel, a foam, a gelatin, a bead, a bandage, and a cellophane.
- (PREVIOUSLY PRESENTED) The device of claim 1, wherein the heparin-related compound is a heparin-related oligiosaccharide of 8-16 sugars.

17-22. (CANCELED)

- (PREVIOUSLY PRESENTED) The device of claim 4, wherein the extracellular matrix further comprises fibronectin or a fibronectin fragment that binds to the bound protein.
- (PREVIOUSLY PRESENTED) The device of 4, wherein the bound protein contains a heparin-binding consensus sequence.
- 25. (PREVIOUSLY PRESENTED) The device of 4, wherein the bound protein contains a glycine-like box, wherein said glycine-like box is from about seven to twelve amino acids and contains at least two Gly residues and two-five basic amino acid residues.
- 26. (PREVIOUSLY PRESENTED) The device of 7, wherein the bound protein contains a glycine-like box, wherein said glycine-like box is from about seven to twelve amino acids and contains at least two Gly residues and two-five basic amino acid residues.
- (PREVIOUSLY PRESENTED) The device of 4, wherein the device is formed in situ in a subject.

Application No.: 10/552,194 Restriction Requirement mailed October 25, 2007 Amendment filed February 21, 2008 Page 4 of 5

- (PREVIOUSLY PRESENTED) The device of 7, wherein the device is formed in situ in a subject.
- (PREVIOUSLY PRESENTED) The device of 12, wherein the device is formed in situ in a subject.
- 30. (PREVIOUSLY PRESENTED) The method of claim 19, wherein the extracellular matrix further comprises fibronectin or a fibronectin fragment that binds to the bound protein and wherein the heparin-related compound is heparan sulfate or heparan sulfate proteoglycan.